Dr Hixson currently serves as chairman of the board of Sequenom, a genetics and molecular diagnostic company. Dr Hixson is also a member of the board of Infinity Pharmaceuticals, a cancer drug discovery and development company.
Dr Hixson has received his PhD in physical biochemistry from Purdue University and an MBA from the University of Chicago. Dr Hixson also received an honorary doctor of science degree from Purdue University.
Ron Najafi, chairman and CEO of NovaBay, said: “I am honored that Harry Hixson, the former president of Amgen, has decided to join the NovaBay board of directors.
“With the perspective that Harry brings to our board from his senior management positions in major companies like Amgen and Abbott and the leadership he has provided to growing earlier stage companies, we expect to benefit significantly from his guidance at NovaBay. The NovaBay board and executive team are looking forward to working with him.”